AstraZeneca, Biogen, Bristol and Eli Lilly among companies with potentially successful drugs

Looking at recently approved drugs and the pipeline of major pharmaceutical companies, there is no shortage of therapies that have the potential to generate significant revenue.

The analytics company Clarivate, in its Annual Drugs to Monitor report, identified 15 drugs with the potential to become blockbusters These drugs are predicted to hit blockbuster status — sales of $1 billion or more — by 2027.

The drug manufacturers on this list include AstraZeneca (AZN), AbbVie (NYSE:ABBV), Bristol-Myers Squibb (NYSE:BMY), Eli Lilly (LLY), Gilead Science (GILD), Johnson & Johnson (JNJ) and Pfizer (PFE).

The report provides a dose of confidence for the pharmaceutical and biotech industries as there are only 37 new molecular entities by 2022, lowest since 2016.

While 2023 doesn’t promise to be a walk in the park, with patent and capital challenges, pharmaceuticals and biotechnology “are on track to unlock technologies,” Clarivate said. revolutionary that can dramatically improve human health”.

Below are some of the therapies that Clarivate estimates have the potential to be successful.

Approved by US FDA in early JanuaryLeqembi, from Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY), poised to become the primary treatment for early to mid-stage Alzheimer’s disease. Monoclonal antibody treatments target beta amyloid plaques in the brain to slow disease progression.

Leqembi is almost certain to be a blockbuster with one key condition: CMS makes a positive National Insurance Decision, something it didn’t for another approved Alzheimer’s treatment. of the company, Aduhelm (aducanumab). CMS will likely make that decision later this year. Should Leqembi be fully approved — it’s currently being expedited — it can assist CMS to make positive decisions.

Leqembi’s list price is $26.5K based on two monthly infusions. Goldman Sachs has predicted the treatment could top global revenue of $15.7 billion by 2035.

Approved in September 2022, Bristol-Myers Squibb’s Sotyktu is one of two plaque psoriasis treatments to make the list. The other is from UCB (OTCPK: UCBJF)(OTCPK: UCBJY) Bimzelx (bimekizumab), a dual IL-17 A/F inhibitor.

Sotyktu, a tyrosine kinase 2 (TYK2) inhibitor, was approved without a “black box warning,” which many analysts consider a significant positive. They also see this approval as taking away Amgen’s market share (AMGN) Otezla (top).

Bristol (BMY) previously claimed Sotyktu could hit peak sales of $4 billion if there were signs of other inflammatory diseases.

With several phase 3 trials underway, capivasertib, a selective ATP-competitive pan-AKT kinase inhibitor from AstraZeneca (AZN), could become a new treatment in the arsenal for breast cancer. In 2022, the company reported that adding capivasertib to Fasdolex (first drug) resulted in 40% reduced risk of disease progression or death compared with Fasdolex alone.

Revenue could reach $3.8 billion by 2038, according to global data.

by GlaxoSmithKline (NYSE:GSK) daprodustat, a HIF prolyl-hydroxylase inhibitor for the treatment of chronic kidney disease in hemodialysis patients with anemia, has an FDA action date of February 1. In October 2022, an advisory panel of the agency overwhelmingly vote in favor of the candidates.

The drug works by promoting erythropoiesis, also known as red blood cell production.

Daprodustat has been approved in Japan. Jefferies had a peak revenue estimate of $1 billion.

AbbVie (ABBV) is developing this new formulation of the standard of care for Parkinson’s patients, carbidopa/levodopa. The medicine is delivered by a pump under the skin.

Clarify what he said that foscarbidopa/foslevodopa is more effective than oral carbidopa/levodopa, has a more flexible dosing, and is more convenient to pump than current and potential competitors.